Education
About Us
Working with TipRanks
Follow Us
Kyntra Bio (KYNB)
NASDAQ:KYNB
KYNB Stock Chart & Stats
$7.83
>-$0.01(-1.28%)
At close: 4:00 PM EST
$7.83
>-$0.01(-1.28%)
Day’s Range― - ―
52-Week Range$4.85 - $21.94
Previous CloseN/A
VolumeN/A
Average Volume (3M)30.76K
Market Cap
$33.25M
Enterprise Value-$66.40M
Total Cash (Recent Filing)$117.97M
Total Debt (Recent Filing)$19.47M
Price to Earnings (P/E)0.2
Beta1.14
Next Earnings
Mar 02, 2026EPS Estimate
-3.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)49.61
Shares Outstanding4,045,445
10 Day Avg. Volume33,010
30 Day Avg. Volume30,760
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)-5.87
Price to Sales (P/S)44.72
P/FCF Ratio-9.58
Enterprise Value/Market Cap-2.00
Enterprise Value/Revenue0.56
Enterprise Value/Gross Profit0.68
Enterprise Value/Ebitda0.52
Forecast
1Y Price Target
$43.00Price Target Upside449.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressInitiation of the FG-3246 Phase 2 monotherapy trial, together with an exploratory FG-3180 diagnostic sub-study, advances the company's clinical momentum and broadens the development pathway for oncology assets.
Financial Flexibility From DivestitureProceeds from the China business divestiture, along with a strong cash balance, enhance financial flexibility and lower near-term reliance on external financing to support multiple programs.
Regulatory Pathway AdvancementPlanned filing of a pivotal Phase III protocol for roxadustat in lower-risk myelodysplastic syndromes signals progress toward a potential regulatory milestone that could be a value inflection for the company.
Bears Say
Cash Runway RiskSponsoring the Phase III low-risk MDS study at an anticipated cost of $50–60 million could reduce cash runway into the second half of 2027 if additional funding is not secured.
Financing And Dilution RiskThe potential need to raise capital to fund trial sponsorship increases the likelihood of equity dilution or additional debt, which may pressure the stock.
Resource Allocation RiskCommitting significant capital to a single pivotal study could divert resources from other programs, slowing progress across the broader pipeline and raising execution risk.
KYNB FAQ
What was Kyntra Bio’s price range in the past 12 months?
Kyntra Bio lowest stock price was $4.85 and its highest was $21.94 in the past 12 months.
What is Kyntra Bio’s market cap?
Kyntra Bio’s market cap is $33.25M.
When is Kyntra Bio’s upcoming earnings report date?
Kyntra Bio’s upcoming earnings report date is Mar 02, 2026 which is in 19 days.
How were Kyntra Bio’s earnings last quarter?
Kyntra Bio released its earnings results on Nov 10, 2025. The company reported $49.61 earnings per share for the quarter, beating the consensus estimate of -$4.007 by $53.617.
Is Kyntra Bio overvalued?
According to Wall Street analysts Kyntra Bio’s price is currently Undervalued.
Does Kyntra Bio pay dividends?
Kyntra Bio does not currently pay dividends.
What is Kyntra Bio’s EPS estimate?
Kyntra Bio’s EPS estimate is -3.89.
How many shares outstanding does Kyntra Bio have?
Kyntra Bio has 4,045,445 shares outstanding.
What happened to Kyntra Bio’s price movement after its last earnings report?
Kyntra Bio reported an EPS of $49.61 in its last earnings report, beating expectations of -$4.007. Following the earnings report the stock price went down -9.636%.
Which hedge fund is a major shareholder of Kyntra Bio?
Currently, no hedge funds are holding shares in KYNB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kyntra Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$43.00 (449.17% Upside)
$43.00 (449.17% Upside)
Hedge Fund Trend
Decreased
By 30.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $33.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 11.2%
Last 30 Days ▼ 11.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-39.27%
Trailing 12-Months
Company Description
Kyntra Bio
Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.
KYNB Company Deck
KYNB Earnings Call
Q3 2025
0:00 / 0:00
KYNB Stock 12 Month Forecast
Average Price Target
$43.00
▲(449.17% Upside)
Technical Analysis
Grace Therapeutics
―
Generation Bio
―
OnKure Therapeutics
―
Senti Biosciences
―
Xilio Therapeutics
―
Ownership Overview
10.61% Insiders
23.76% Mutual Funds
11.09% Other Institutional Investors
50.67% Public Companies and
Individual Investors